JP6949002B6 - ニコチンアミドモノヌクレオチド誘導体及びそれらの使用 - Google Patents
ニコチンアミドモノヌクレオチド誘導体及びそれらの使用 Download PDFInfo
- Publication number
- JP6949002B6 JP6949002B6 JP2018505479A JP2018505479A JP6949002B6 JP 6949002 B6 JP6949002 B6 JP 6949002B6 JP 2018505479 A JP2018505479 A JP 2018505479A JP 2018505479 A JP2018505479 A JP 2018505479A JP 6949002 B6 JP6949002 B6 JP 6949002B6
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- carbocyclyl
- salt
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)(C)C(SCCOP(OCCSC(C(C)(C)C)=O)(OC[C@](C(C1O)N)O[C@]1[n+]1cccc(C(*)O)c1)=O)=O Chemical compound CC(C)(C)C(SCCOP(OCCSC(C(C)(C)C)=O)(OC[C@](C(C1O)N)O[C@]1[n+]1cccc(C(*)O)c1)=O)=O 0.000 description 12
- KGUMNRYFUFLBGA-UHFFFAOYSA-N NC(C1=CNC=CC1)=O Chemical compound NC(C1=CNC=CC1)=O KGUMNRYFUFLBGA-UHFFFAOYSA-N 0.000 description 3
- YGYLYUIRSJSFJS-UHFFFAOYSA-N CC(C(OCc1ccccc1)=O)N Chemical compound CC(C(OCc1ccccc1)=O)N YGYLYUIRSJSFJS-UHFFFAOYSA-N 0.000 description 2
- SJHNZXZSCFXAGR-KZHXMJBDSA-O CC(C)(CO)C(SCCOP(NCc1ccccc1)(OC[C@H](C(C1O)O)O[C@H]1[n+]1cccc(C(N)=O)c1)=O)=O Chemical compound CC(C)(CO)C(SCCOP(NCc1ccccc1)(OC[C@H](C(C1O)O)O[C@H]1[n+]1cccc(C(N)=O)c1)=O)=O SJHNZXZSCFXAGR-KZHXMJBDSA-O 0.000 description 1
- ZZJYAUAQTTWWJU-UHFFFAOYSA-N CC(C)OC(C1(CC1)NP(Oc1ccccc1)(Cl)=O)=O Chemical compound CC(C)OC(C1(CC1)NP(Oc1ccccc1)(Cl)=O)=O ZZJYAUAQTTWWJU-UHFFFAOYSA-N 0.000 description 1
- CJAUMQKNYUQPPQ-UHFFFAOYSA-N CC(C)OC(C1(CC1)NPOc1ccccc1)=O Chemical compound CC(C)OC(C1(CC1)NPOc1ccccc1)=O CJAUMQKNYUQPPQ-UHFFFAOYSA-N 0.000 description 1
- VJQRIMSGVFNASH-MPLPKVEKSA-O CC(C)OC([C@H](C)N[P@](OC[C@H](C1O)OCC1(C[n+]1cccc(C(N)=O)c1)O)(Oc1ccccc1)=O)=O Chemical compound CC(C)OC([C@H](C)N[P@](OC[C@H](C1O)OCC1(C[n+]1cccc(C(N)=O)c1)O)(Oc1ccccc1)=O)=O VJQRIMSGVFNASH-MPLPKVEKSA-O 0.000 description 1
- WUFKSCYCLPLPAD-OFGTXKLQSA-N CC1(C)O[C@H]2C(C3)(C3(C=CC3)C=C3C(N)=O)OC(CO)[C@H]2O1 Chemical compound CC1(C)O[C@H]2C(C3)(C3(C=CC3)C=C3C(N)=O)OC(CO)[C@H]2O1 WUFKSCYCLPLPAD-OFGTXKLQSA-N 0.000 description 1
- UAFVODYMPYUSEM-FCQVWKKNSA-N CC1(C)O[C@H]2C(C3)(C3/C=C\C/C(/C(N)=O)=C\N)OC(CO)[C@H]2O1 Chemical compound CC1(C)O[C@H]2C(C3)(C3/C=C\C/C(/C(N)=O)=C\N)OC(CO)[C@H]2O1 UAFVODYMPYUSEM-FCQVWKKNSA-N 0.000 description 1
- OYTJMIJRDXPLRE-VECWZWDRSA-N CC1(C)O[C@H]2C(C3)([C@@H]3N(C=CC3)C=C3C(N)=O)OC(CO)[C@H]2O1 Chemical compound CC1(C)O[C@H]2C(C3)([C@@H]3N(C=CC3)C=C3C(N)=O)OC(CO)[C@H]2O1 OYTJMIJRDXPLRE-VECWZWDRSA-N 0.000 description 1
- QFLIKAWCLYFQFD-SPDVFEMOSA-N CC1(C)O[C@H]2C3(CC3)OC(CO)[C@H]2O1 Chemical compound CC1(C)O[C@H]2C3(CC3)OC(CO)[C@H]2O1 QFLIKAWCLYFQFD-SPDVFEMOSA-N 0.000 description 1
- CKEIHRGHSNBNBX-DHVVTYNASA-N CC1(C)O[C@H]2[C@H](N(C=CC3)C=C3[C@@H](N)O)OC(COP(OCC3)(OC3c(cc3Cl)ccc3F)=O)[C@H]2O1 Chemical compound CC1(C)O[C@H]2[C@H](N(C=CC3)C=C3[C@@H](N)O)OC(COP(OCC3)(OC3c(cc3Cl)ccc3F)=O)[C@H]2O1 CKEIHRGHSNBNBX-DHVVTYNASA-N 0.000 description 1
- BBDQDTSBXDTVIF-UHFFFAOYSA-N CCC(CC)COC(C(C)N)=O Chemical compound CCC(CC)COC(C(C)N)=O BBDQDTSBXDTVIF-UHFFFAOYSA-N 0.000 description 1
- CSURKLFFMMBEFL-UHFFFAOYSA-N CCC(CC)COC(C(C)NP(Oc1ccccc1)(Oc(cc1)ccc1[N+]([O-])=O)=O)=O Chemical compound CCC(CC)COC(C(C)NP(Oc1ccccc1)(Oc(cc1)ccc1[N+]([O-])=O)=O)=O CSURKLFFMMBEFL-UHFFFAOYSA-N 0.000 description 1
- CFNSDJDHERKHOM-JCOHPEILSA-O C[C@@H](C(OCC(C)(C)C)=O)NP(OCC(C(C1O)O)O[C@H]1[n+]1cccc(C(N)=O)c1)(Oc1cccc2ccccc12)=O Chemical compound C[C@@H](C(OCC(C)(C)C)=O)NP(OCC(C(C1O)O)O[C@H]1[n+]1cccc(C(N)=O)c1)(Oc1cccc2ccccc12)=O CFNSDJDHERKHOM-JCOHPEILSA-O 0.000 description 1
- VNXOOJOHDADCRQ-ICKKKKQQSA-O C[C@@H](C(OCC(C)(C)C)=O)NP(OCC(N[C@H](C1O)[N+]2=CC(C(N)=O)=CCC2)=C1O)(Oc1cccc2ccccc12)=O Chemical compound C[C@@H](C(OCC(C)(C)C)=O)NP(OCC(N[C@H](C1O)[N+]2=CC(C(N)=O)=CCC2)=C1O)(Oc1cccc2ccccc12)=O VNXOOJOHDADCRQ-ICKKKKQQSA-O 0.000 description 1
- LBJGYNJPYJGERP-NVRZYUOXSA-O C[C@@H](C(OCc1ccccc1)=O)NP(COC[C@H](C(C1O)O)O[C@H]1[N+]1=CC(C(N)=O)=CCC1)OC1=CCC(C)CC1 Chemical compound C[C@@H](C(OCc1ccccc1)=O)NP(COC[C@H](C(C1O)O)O[C@H]1[N+]1=CC(C(N)=O)=CCC1)OC1=CCC(C)CC1 LBJGYNJPYJGERP-NVRZYUOXSA-O 0.000 description 1
- QXINWDCEJFZACH-UHFFFAOYSA-N Cc(cc1)ccc1OP(Cl)=O Chemical compound Cc(cc1)ccc1OP(Cl)=O QXINWDCEJFZACH-UHFFFAOYSA-N 0.000 description 1
- UGNCMWPJBQJOJD-LMVMCUILSA-O NC(c1c[n+]([C@@H](C2O)O[C@H](COP(OCC3)(OC3c3cc(F)cc(F)c3)=O)C2O)ccc1)=O Chemical compound NC(c1c[n+]([C@@H](C2O)O[C@H](COP(OCC3)(OC3c3cc(F)cc(F)c3)=O)C2O)ccc1)=O UGNCMWPJBQJOJD-LMVMCUILSA-O 0.000 description 1
- DZVCCMZCLSCPIW-KYETZVDKSA-O NC(c1ccc[n+](C([C@@H]2O)OC(COP(OCC3)(OC3c(cc3Cl)ccc3F)=O)[C@H]2O)c1)=O Chemical compound NC(c1ccc[n+](C([C@@H]2O)OC(COP(OCC3)(OC3c(cc3Cl)ccc3F)=O)[C@H]2O)c1)=O DZVCCMZCLSCPIW-KYETZVDKSA-O 0.000 description 1
- HMSVOLZGLSFOMK-UHFFFAOYSA-N O=P(OCC1OC(CC2)C2C1)Oc1ccccc1 Chemical compound O=P(OCC1OC(CC2)C2C1)Oc1ccccc1 HMSVOLZGLSFOMK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
- C07H11/04—Phosphates; Phosphites; Polyphosphates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201447P | 2015-08-05 | 2015-08-05 | |
| US62/201,447 | 2015-08-05 | ||
| PCT/US2016/045855 WO2017024255A1 (en) | 2015-08-05 | 2016-08-05 | Nicotinamide mononucleotide derivatives and their uses |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018522042A JP2018522042A (ja) | 2018-08-09 |
| JP2018522042A5 JP2018522042A5 (enExample) | 2019-09-19 |
| JP6949002B2 JP6949002B2 (ja) | 2021-10-13 |
| JP6949002B6 true JP6949002B6 (ja) | 2021-11-17 |
Family
ID=57944181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505479A Active JP6949002B6 (ja) | 2015-08-05 | 2016-08-05 | ニコチンアミドモノヌクレオチド誘導体及びそれらの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US9855289B2 (enExample) |
| EP (1) | EP3331894B1 (enExample) |
| JP (1) | JP6949002B6 (enExample) |
| KR (1) | KR102354784B1 (enExample) |
| CN (1) | CN108137639B (enExample) |
| AU (1) | AU2016302005B2 (enExample) |
| BR (1) | BR112018002168B1 (enExample) |
| CA (1) | CA2994553C (enExample) |
| DK (1) | DK3331894T3 (enExample) |
| EA (1) | EA035664B1 (enExample) |
| ES (1) | ES2862170T3 (enExample) |
| IL (1) | IL257327B (enExample) |
| MX (1) | MX2018001363A (enExample) |
| PL (1) | PL3331894T3 (enExample) |
| PT (1) | PT3331894T (enExample) |
| WO (1) | WO2017024255A1 (enExample) |
| ZA (1) | ZA201801196B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9855289B2 (en) | 2015-08-05 | 2018-01-02 | Metro International Biotech, Llc | Nicotinamide mononucleotide derivatives and their uses |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| US10611790B2 (en) | 2015-11-02 | 2020-04-07 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
| ES2948968T3 (es) | 2016-04-20 | 2023-09-22 | Chromadex Inc | Uso del ribósido de ácido nicotínico o derivados del ribósido de nicotinamida, y derivados reducidos de los mismos, como precursores que aumentan el NAD++ |
| US20200009170A1 (en) * | 2016-09-13 | 2020-01-09 | Megumi Tanaka | Sleep display agent property and method for improving sleep disorders |
| US20190328761A1 (en) | 2016-12-21 | 2019-10-31 | Newsouth Innovations Pty Limited | Methods for enhancing vascular density |
| US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| WO2019152416A1 (en) | 2018-01-30 | 2019-08-08 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| US11814652B2 (en) * | 2018-03-22 | 2023-11-14 | Oriental Yeast Co., Ltd. | Pluripotent stem cell differentiation-promoting agent |
| EP3794005B1 (en) | 2018-05-15 | 2025-10-22 | Jumpstart Fertility Pty Ltd | Inorganic salts of nicotinic acid mononucleotide as anti-aging agents |
| WO2020131578A2 (en) * | 2018-12-17 | 2020-06-25 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| WO2020174492A1 (en) | 2019-02-25 | 2020-09-03 | Celagenex Research (India) Pvt. Ltd. | Synergistic bioactive compositions for enhancing cellular energy |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| US10618927B1 (en) | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
| AU2020288608B2 (en) * | 2019-06-05 | 2025-04-10 | Société des Produits Nestlé S.A. | Reduced nicotinamideribosides for the treatment/prevention of liver disease |
| JP7675061B2 (ja) | 2019-07-19 | 2025-05-12 | バイオシント アクチェンゲゼルシャフト | ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用 |
| CN114423439B (zh) | 2019-09-09 | 2024-12-31 | 努瓦米德股份有限公司 | Nmn用于预防和/或治疗疼痛的用途及相应组合物 |
| FR3100449B1 (fr) | 2019-09-09 | 2022-08-26 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes |
| FR3102058A1 (fr) | 2019-10-18 | 2021-04-23 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes |
| CN112823778B (zh) * | 2019-11-21 | 2024-06-14 | 百瑞全球有限公司 | 毛发护理组合物及其制备方法 |
| FR3103702B1 (fr) | 2019-11-28 | 2022-02-11 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes |
| FR3106056B1 (fr) | 2020-01-13 | 2021-12-17 | Nuvamid | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes |
| FR3107897B1 (fr) * | 2020-03-06 | 2023-05-26 | Nuvamid Sa | Dérivés de nicotinamide mononucléotides |
| FR3108031B1 (fr) | 2020-03-12 | 2024-02-16 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes |
| FR3108032B1 (fr) * | 2020-03-12 | 2024-02-16 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes |
| KR20220160611A (ko) * | 2020-03-30 | 2022-12-06 | 오리엔탈고우보고오교가부시끼가이샤 | 줄기세포의 염색체 안정화제 |
| AU2021260118A1 (en) * | 2020-04-24 | 2022-11-17 | Nuvamid Sa | Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus |
| EP3901160A1 (en) * | 2020-04-25 | 2021-10-27 | Nuvamid SA | Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus |
| JP7597396B2 (ja) * | 2020-05-05 | 2024-12-10 | コナゲン インコーポレイテッド | 微生物プロセスを介したｎｍｎおよびその誘導体の生成 |
| US20230210746A1 (en) | 2020-05-20 | 2023-07-06 | Nuvamid Sa | Anti-aging cosmetic compositions comprising nmn |
| FR3110410A1 (fr) | 2020-05-20 | 2021-11-26 | Nuvamid Sa | Compositions cosmétiques anti-âge comprenant de la NMN |
| FR3110836B1 (fr) | 2020-05-29 | 2023-06-16 | Nuvamid | Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence |
| CN111548383B (zh) * | 2020-06-11 | 2023-04-18 | 湖南和泰康瑞生物技术有限公司 | 一种β-烟酰胺单核苷酸的工艺制备方法 |
| CN111956670A (zh) * | 2020-08-31 | 2020-11-20 | 杭州伊瑟奇生物科技有限公司 | 一种间充质干细胞及其活性因子复合物冻干品的制备方法 |
| WO2022047779A1 (zh) * | 2020-09-07 | 2022-03-10 | 音芙医药科技(上海)有限公司 | 烟酰胺单核苷酸在制备提高损伤皮肤肌膜中Na+-K+-ATP酶水平试剂中的应用 |
| CN112094362B (zh) * | 2020-09-29 | 2022-04-12 | 四川大学华西医院 | 烟酰胺核糖或单核苷酸类似物-大分子载体轭合物及制法和应用 |
| WO2022094916A1 (zh) * | 2020-11-06 | 2022-05-12 | 中国科学院深圳先进技术研究院 | 一种提高烟酰胺磷酸核糖转移酶活性的方法及其组合物 |
| CN112500445B (zh) * | 2020-12-04 | 2022-11-29 | 黄冈鲁班药业股份有限公司 | β-烟酰胺核糖的制备方法 |
| IT202100005054A1 (it) * | 2021-03-04 | 2022-09-04 | Azienda Ospedaliero Univ Di Parma | Composto farmaceutico per l’uso in un trattamento terapeutico dell’infezione cronica da hbv e metodo per l’identificazione di linfociti esauriti |
| KR102633321B1 (ko) * | 2021-05-11 | 2024-02-05 | 연세대학교 산학협력단 | 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물 |
| CA3219033A1 (en) | 2021-05-27 | 2022-12-01 | Metro International Biotech, Llc | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use |
| CN115304655B (zh) * | 2021-11-23 | 2024-11-22 | 中立安(北京)医药科技有限公司 | 烟酰胺单核苷类衍生物及其制备方法和应用 |
| CN118541157A (zh) | 2021-12-22 | 2024-08-23 | 麦德龙国际生物科技有限责任公司 | 用于治疗炎症的组合物 |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
| CN114540283B (zh) * | 2022-01-27 | 2023-10-20 | 中国农业科学院北京畜牧兽医研究所 | 用于牛体外胚胎生产的高效玻璃化冷冻方法 |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| CN115611960A (zh) * | 2022-11-18 | 2023-01-17 | 翔鹏(北京)生物科技有限公司 | 一种人体辅酶i前体的制备方法 |
| CN118593362B (zh) * | 2024-06-26 | 2026-05-12 | 山东福瑞达生物股份有限公司 | 一种nmn油悬液的制备方法与应用 |
| WO2026053929A1 (ja) * | 2024-09-06 | 2026-03-12 | 国立大学法人 東京大学 | 細胞内ａｔｐおよび細胞内ｎａｄの量を増加させるための組成物 |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3201389A (en) | 1962-09-24 | 1965-08-17 | Kyowa Hakko Kogyo Kk | Method for preparing ribonucleoside-5'-phosphates or their salts from ribonucleosides |
| US3451997A (en) | 1965-11-30 | 1969-06-24 | Kyowa Hakko Kogyo Kk | Monothio-phosphate ester catalysis for preparation of ribonucleoside derivatives |
| US4411995A (en) | 1981-09-28 | 1983-10-25 | Massachusetts Institute Of Technology | Synthesis of nicotinamide cofactors |
| US5318508A (en) | 1991-03-15 | 1994-06-07 | Elvira Osthold | Nail corrective brace |
| RS20100077A (sr) | 2001-04-30 | 2010-10-31 | Trommsdorff Gmbh. & Co. Kg. Arzneimittel | Farmaceutski aktivni estri uridina |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US20040224039A1 (en) | 2003-02-12 | 2004-11-11 | Donald Brucker | Compositions and methods for the treatment of diseases and disorder associated with oxidative damage |
| WO2006072809A2 (en) | 2003-10-31 | 2006-07-13 | Robarts Research Institute | Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions |
| CN1964627B (zh) | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| US7998974B2 (en) | 2005-03-03 | 2011-08-16 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| EP2805719A1 (en) | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| US20070149466A1 (en) | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EP1915053A2 (en) | 2005-08-12 | 2008-04-30 | Merck & Co., Inc. | Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives |
| JP5063878B2 (ja) | 2005-08-30 | 2012-10-31 | 扶桑薬品工業株式会社 | 硫化水素塩を含有する消化器系疾患の予防／治療用組成物 |
| WO2007061798A2 (en) | 2005-11-18 | 2007-05-31 | Cornell Research Foundation, Inc. | Nicotinoyl riboside compositions and methods of use |
| US20080226750A1 (en) | 2006-04-20 | 2008-09-18 | Fred Hutchinson Cancer Research Center | Methods, Compositions and Articles of Manufacture for Treating Shock and Other Adverse Conditions |
| US20080318892A1 (en) | 2006-04-28 | 2008-12-25 | John Geoffrey Pickering | Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad |
| CA2676609A1 (en) | 2007-01-26 | 2008-07-31 | Washington University | Methods and compositions for treating neuropathies |
| TW200936146A (en) | 2007-11-29 | 2009-09-01 | Metabasis Therapeutics Inc | Antiviral nucleoside compounds |
| CN101497638B (zh) | 2008-01-30 | 2012-09-26 | 中国科学院大连化学物理研究所 | 一种nad+类似物及其合成和应用 |
| PL2280973T3 (pl) | 2008-04-23 | 2013-05-31 | Gilead Sciences Inc | Analogi karba-nukleozydowe do leczenia przeciwwirusowego |
| US11219696B2 (en) | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
| CN101601679B (zh) | 2009-03-17 | 2011-08-10 | 中国人民解放军第二军医大学 | 一种烟酰胺单核苷酸的应用 |
| WO2010135520A1 (en) * | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
| US20130102009A1 (en) | 2010-04-15 | 2013-04-25 | Han Dai | Sirtuin activators and activation assays |
| TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| US8481711B2 (en) | 2010-07-06 | 2013-07-09 | Hidenori Kamanishi | Neurite outgrowth agent |
| AR082885A1 (es) | 2010-09-03 | 2013-01-16 | Genentech Inc | Compuestos y composiciones para la inhibicion de nampt |
| AR082886A1 (es) | 2010-09-03 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones farmaceuticas que los contienen |
| CN106986856A (zh) | 2010-09-03 | 2017-07-28 | 福马Tm有限责任公司 | 作为用于治疗疾病诸如癌症的nampt抑制剂的4‑{[(吡啶‑3‑基‑甲基)氨基羰基]氨基}苯‑砜衍生物 |
| WO2012094343A1 (en) * | 2011-01-05 | 2012-07-12 | Trilink Biotechnologies | Chemically substituted thermosensitive probes and cofactors for hot start ligation |
| WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
| US20120107888A1 (en) | 2011-02-17 | 2012-05-03 | Qteros, Inc. | Modulation of fermentation products through vitamin supplementation |
| JP5978293B2 (ja) | 2011-05-04 | 2016-08-24 | フォーマ ティーエム， エルエルシー． | Ｎａｍｐｔを阻害するための新規な化合物および組成物 |
| US20120328526A1 (en) | 2011-06-27 | 2012-12-27 | University Of Maryland, Baltimore | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof |
| EP3345901A3 (en) | 2011-06-29 | 2018-09-12 | President and Fellows of Harvard College | Small molecules as antiaging agents |
| US20130143835A1 (en) | 2011-12-05 | 2013-06-06 | Medivir Ab | HCV Polymerase Inhibitors |
| WO2013127268A1 (en) | 2012-03-02 | 2013-09-06 | Genentech,Inc. | Amido-benzyl sulfone and sulfonamide derivatives |
| WO2013130943A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Alkyl-and di-substituted amido-benzyl sulfonamide derivatives |
| SG10201701894SA (en) | 2012-03-02 | 2017-05-30 | Genentech Inc | Amido-Benzyl Sulfone and Sulfoxide Derivatives |
| HRP20170411T1 (hr) | 2012-03-02 | 2017-06-16 | Genentech, Inc. | Amido spirocilični amidni i sulfonamidni derivati |
| EP2820017B1 (en) | 2012-03-02 | 2016-12-21 | Genentech, Inc. | Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives |
| MD20140134A2 (ro) | 2012-05-22 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice |
| EP2872128B1 (en) | 2012-07-16 | 2020-02-19 | Cornell University | Nicotinamide riboside to treat hearing loss |
| WO2014059034A2 (en) | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
| CN102876759A (zh) | 2012-10-29 | 2013-01-16 | 尚科生物医药（上海）有限公司 | 尼克酰胺腺嘌呤二核苷酸的制备方法 |
| WO2014074715A1 (en) | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
| WO2014111906A1 (en) | 2013-01-21 | 2014-07-24 | Ecole Polytechnique Federale De Lausanne (Epfl) | Bioluminescence imaging of small biomolecules |
| US20140271355A1 (en) | 2013-03-15 | 2014-09-18 | Sabre Intellectual Property Holdings Llc | Apparatus and process for focused gas phase application of biocide |
| WO2014146044A1 (en) | 2013-03-15 | 2014-09-18 | Washington University | Administration of nicotinamide mononucleotide in the treatment of disease |
| GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| WO2015069860A1 (en) | 2013-11-06 | 2015-05-14 | President And Fellows Of Harvard College | Biological production of nad precursors and analogs |
| US10398701B2 (en) | 2013-11-12 | 2019-09-03 | Ortho-Nutra, Llc | Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine |
| BR112016010422B1 (pt) | 2013-11-12 | 2021-08-31 | Ortho-Nutra, Llc | Suplemento dietético e método de tratamento para melhorar o desempenho ou energia física em um indivíduo |
| EP3068364B1 (en) | 2013-11-14 | 2021-11-03 | Metro Biotech NSW Pty Ltd | Nad+ precursor selected from nmn, naad, namn, or a pharmaceutically acceptable salt thereof, for use in treating a side effect of chemotherapy and/or radiotherapy in a subject |
| CN104367587B (zh) | 2013-12-06 | 2018-06-29 | 中国人民解放军第二军医大学 | 烟酰胺单核苷酸在制备促脑缺血后神经再生药物中的应用 |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| JP2017511304A (ja) | 2014-03-13 | 2017-04-20 | ソーク インスティチュート フォー バイオロジカル スタディーズ | フェキサラミン類似体ならびに作製方法および使用方法 |
| US20150258052A1 (en) | 2014-03-13 | 2015-09-17 | Salk Institute For Biological Studies | Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue |
| US10316054B2 (en) | 2014-06-02 | 2019-06-11 | Glaxosmithkline Intellectual Property (No. 2) Limited | Preparation and use of crystalline beta-D-nicotinamide riboside |
| EP3151671A4 (en) | 2014-06-03 | 2018-03-07 | Sulfagenix, Inc. | Methods and compositions for treating nitric oxide deficiency disorders and related conditions |
| RU2016149767A (ru) | 2014-06-06 | 2018-07-16 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Аналоги никотинамидрибозида и фармацевтические композиции и их применение |
| CA2956163C (en) | 2014-07-24 | 2023-01-10 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| US10653782B2 (en) | 2014-11-25 | 2020-05-19 | Nortwestern University | Retroviral particles expressing Sirt1 embedded within PPCN |
| WO2016093515A1 (ko) | 2014-12-09 | 2016-06-16 | (주)아모레퍼시픽 | 장수 유전자 활성화용 조성물 |
| ES2963057T3 (es) | 2015-03-09 | 2024-03-25 | Grace W R & Co | Forma cristalina de ribósido de nicotinamida |
| CN104817604B (zh) | 2015-03-16 | 2017-08-04 | 邦泰生物工程(深圳)有限公司 | 一种β‑烟酰胺单核苷酸的纯化方法 |
| EP3271456A1 (en) | 2015-03-18 | 2018-01-24 | The Regents of the University of California | Methods of preventing and reversing stem cell aging |
| US20160355539A1 (en) | 2015-06-04 | 2016-12-08 | Chromadex, Inc. | Selective solvent free phosphorylation |
| US20180177703A1 (en) | 2015-06-25 | 2018-06-28 | N.V. Perricone Llc | Niacinamide Mononucleotide Formulations For Skin Aging |
| US9855289B2 (en) | 2015-08-05 | 2018-01-02 | Metro International Biotech, Llc | Nicotinamide mononucleotide derivatives and their uses |
| TW201713774A (zh) | 2015-08-06 | 2017-04-16 | Kohjin Life Sciences Co Ltd | 含有β-菸鹼醯胺單核苷酸的酵母萃取物及其製造方法 |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| CA3001483A1 (en) | 2015-10-07 | 2017-04-13 | Joel HUIZENGA | Resetting biological pathways for defending against and repairing deterioration from human aging |
| US10611790B2 (en) | 2015-11-02 | 2020-04-07 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
| EP3401323B1 (en) | 2015-12-21 | 2020-07-08 | Showa Denko K.K. | Nicotinamide mononucleotide derivative and salt thereof, method for producing the same, topical agent, cosmetic and food additive |
| EP3187180A1 (en) | 2015-12-28 | 2017-07-05 | Ludwig-Maximilians-Universität München | Adenosylhomocysteinase binding substances for medical use |
| US11248018B2 (en) | 2016-02-23 | 2022-02-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Process for preparation of nicotinamide riboside (NR) and cosmetic composition comprising (NR and a phosphate-binding agent |
| EP3429354A4 (en) | 2016-03-16 | 2020-03-25 | Chromadex Inc. | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF AND METHOD FOR THE PRODUCTION THEREOF |
| ES2948968T3 (es) | 2016-04-20 | 2023-09-22 | Chromadex Inc | Uso del ribósido de ácido nicotínico o derivados del ribósido de nicotinamida, y derivados reducidos de los mismos, como precursores que aumentan el NAD++ |
| WO2017218580A1 (en) | 2016-06-14 | 2017-12-21 | Rejuvenation Therapeutics Corporation | Synthetic methods for the preparation of nicotinamide riboside and related compounds |
| CN107889504B (zh) | 2016-07-30 | 2021-07-27 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法 |
| WO2018023209A1 (zh) | 2016-07-30 | 2018-02-08 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法 |
| WO2017185549A1 (zh) | 2016-07-30 | 2017-11-02 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法2 |
| CN108026132B (zh) | 2016-07-30 | 2021-08-13 | 邦泰生物工程(深圳)有限公司 | 一种烟酰胺单核苷酸的纯化方法 |
| WO2018023208A1 (zh) | 2016-07-30 | 2018-02-08 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法 |
| CN107889505B (zh) | 2016-07-30 | 2021-05-25 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法 |
| WO2018047715A1 (ja) | 2016-09-06 | 2018-03-15 | 協和発酵バイオ株式会社 | β－ニコチンアミドモノヌクレオチドの結晶及びその製造方法 |
| JP7002713B2 (ja) | 2016-09-09 | 2022-01-20 | 日本電気株式会社 | 量子鍵配送システム用の送信装置、受信装置、量子鍵配送方法、および量子鍵配送プログラム |
| US10898738B2 (en) | 2016-09-13 | 2021-01-26 | Megumi Tanaka | Visual function printing agent, and method for improving visual functions |
| US20200009170A1 (en) | 2016-09-13 | 2020-01-09 | Megumi Tanaka | Sleep display agent property and method for improving sleep disorders |
| NZ803738A (en) | 2016-11-11 | 2024-05-31 | Chromadex Inc | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| US20190328761A1 (en) | 2016-12-21 | 2019-10-31 | Newsouth Innovations Pty Limited | Methods for enhancing vascular density |
| CN106755209B (zh) | 2016-12-29 | 2021-07-23 | 苏州汉酶生物技术有限公司 | 一种酶法制备β-烟酰胺单核苷酸的方法 |
| EP3568488A4 (en) | 2017-01-13 | 2020-09-23 | The Regents of The University of Colorado, A Body Corporate | METHODS OF TREATMENT OF HYPERTENSION AND ARTERIAL RIGIDITY |
| US11634690B2 (en) | 2017-01-31 | 2023-04-25 | Oriental Yeast Co., Ltd. | Agent for accelerating growth of pluripotent stem cells |
| JP6920071B2 (ja) | 2017-02-16 | 2021-08-18 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | アディポネクチン分泌向上剤 |
| AU2018250242B2 (en) | 2017-04-05 | 2021-07-15 | Cornell University | Beta-nicotinate ester nucleotides and processes for preparing same |
| AU2018309558A1 (en) | 2017-07-31 | 2020-02-27 | Newsouth Innovations Pty Limited | Methods for increasing fertility |
| WO2019152416A1 (en) | 2018-01-30 | 2019-08-08 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| US20210388018A1 (en) | 2018-10-01 | 2021-12-16 | Cornell University | Methyl and ethyl nicotinate-riboside-5-phosphates, preparation thereof and methods of use thereof |
| KR20210108400A (ko) | 2018-12-10 | 2021-09-02 | 크로마덱스 아이엔씨. | 니코티노일 리보사이드 및 이의 유도체의 결정질 형태 및 이의 제조 방법 |
| CN113811310B (zh) | 2019-03-22 | 2023-03-24 | 麦德龙国际生物科技有限责任公司 | 包括烟酰胺核苷的磷衍生物的组合物以及用于调节烟酰胺腺嘌呤二核苷酸的方法 |
| US10618927B1 (en) | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| US20230210746A1 (en) | 2020-05-20 | 2023-07-06 | Nuvamid Sa | Anti-aging cosmetic compositions comprising nmn |
| CA3219033A1 (en) | 2021-05-27 | 2022-12-01 | Metro International Biotech, Llc | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use |
-
2016
- 2016-08-05 US US15/512,388 patent/US9855289B2/en active Active
- 2016-08-05 PL PL16833957T patent/PL3331894T3/pl unknown
- 2016-08-05 EP EP16833957.0A patent/EP3331894B1/en active Active
- 2016-08-05 CN CN201680059161.5A patent/CN108137639B/zh active Active
- 2016-08-05 PT PT168339570T patent/PT3331894T/pt unknown
- 2016-08-05 KR KR1020187006160A patent/KR102354784B1/ko active Active
- 2016-08-05 ES ES16833957T patent/ES2862170T3/es active Active
- 2016-08-05 BR BR112018002168-7A patent/BR112018002168B1/pt active IP Right Grant
- 2016-08-05 CA CA2994553A patent/CA2994553C/en active Active
- 2016-08-05 EA EA201890435A patent/EA035664B1/ru unknown
- 2016-08-05 MX MX2018001363A patent/MX2018001363A/es unknown
- 2016-08-05 WO PCT/US2016/045855 patent/WO2017024255A1/en not_active Ceased
- 2016-08-05 AU AU2016302005A patent/AU2016302005B2/en active Active
- 2016-08-05 JP JP2018505479A patent/JP6949002B6/ja active Active
- 2016-08-05 DK DK16833957.0T patent/DK3331894T3/da active
-
2017
- 2017-03-20 US US15/463,683 patent/US9919003B2/en active Active
-
2018
- 2018-01-23 US US15/877,597 patent/US10548913B2/en active Active
- 2018-02-04 IL IL257327A patent/IL257327B/en unknown
- 2018-02-21 ZA ZA2018/01196A patent/ZA201801196B/en unknown
-
2019
- 2019-12-13 US US16/713,711 patent/US11464796B2/en active Active
-
2022
- 2022-07-26 US US17/873,577 patent/US11878027B2/en active Active
-
2023
- 2023-11-21 US US18/516,416 patent/US12485135B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6949002B2 (ja) | ニコチンアミドモノヌクレオチド誘導体及びそれらの使用 | |
| US11180521B2 (en) | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof | |
| KR101608604B1 (ko) | 티오아세테이트 화합물, 조성물 및 사용 방법 | |
| CN111116492B (zh) | 氘代苯甲氨嘧啶二酮衍生物及其用途 | |
| JP2021063081A (ja) | β−ニコチンアミドモノヌクレオチドの結晶形態 | |
| US10611790B2 (en) | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases | |
| JP2022523864A (ja) | ニコチンアミドリボシドのリン誘導体を含む組成物及びニコチンアミドアデニンジヌクレオチドのモジュレーションのための方法 | |
| KR20170008320A (ko) | 니코틴아미드 리보시드 유사체 및 그의 제약 조성물 및 용도 | |
| CN104292125A (zh) | 萘衍生物及其在药物上的应用 | |
| KR20140105598A (ko) | [1,2,4]트리아졸로피리딘 및 포스포디에스테라제 억제제로서의 이의 용도 | |
| CN110240557A (zh) | 吡咯烷酰胺衍生物及其用途 | |
| CN118695860A (zh) | 作为kv7通道激活剂的吡唑基化合物 | |
| CN118678954A (zh) | 作为kv7通道激活剂的吡唑基化合物 | |
| ES2242096T3 (es) | H-heterociclil hidrazidas como agentes neurotroficos. | |
| ES2278078T3 (es) | Derivados de triazepina como agentes neurotroficos. | |
| CN108689906A (zh) | 吲哚取代的酰肼衍生物及其用途 | |
| CN108863948A (zh) | 嘧啶取代的酰肼衍生物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20190718 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190731 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190731 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190718 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200519 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200813 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200827 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210405 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210907 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210921 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6949002 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |